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EDITORIAL

Traumatic brain injury
Traumatic brain injury (TBI) stands as a major cause of mortality and

with the EP2 receptor activates adenylate cyclase and phosphory-

morbidity around the world. More than 30% of injury-related deaths

lates various cellular targets can lead to multiple neuroprotective

in the United States involve TBI.1,2 TBI entails two phases of injury,

processes, including anti-inflammation. In a similar fashion, Greig

namely an initial head trauma via an external force that results in

and co-investigators9 reveal that the small molecular weight drug

mechanical damage to brain tissue and a secondary biochemical cas-

(-)-phenserine tartrate (PhenT), originally developed for Alzheimer's

cades including inflammation, apoptosis, oxidative stress, and other

disease, effectively abrogates mild and moderate TBI via mitigation

pathophysiological complications that propel further brain degen-

of multiple components of programmed neuronal cell death, includ-

eration.3,4 Treatment options for TBI remain limited, indicating an

ing oxidative stress, glutamate excitotoxicity, neuroinflammation,

urgent need to examine novel therapeutic modalities designed to

and effectively reversed injury-induced gene pathways leading to

protect or to regenerate the injured brain.

chronic neurodegeneration. Both PGE2 and PhenT treatments pro-

This special issue compiles recent advances in TBI research focused on cell-based regenerative medicine and pharmacologic ther-

duced motor and cognitive improvements in TBI animals,8,9 further

increasing their clinical application potential.

apies. We envision that rigorous translational research will provide

Finally, another closely relevant traumatic disease, spinal cord

the necessary testbed for ushering safe and effective therapeutics

injury (SCI) is included in this issue. The research group of Ibarra

from the laboratory to the clinic.

reveals that immunization with neural derived peptides possesses

Yasuhara and colleagues5 review the field of cell therapy for TBI

neurogenic and regenerative properties which render motor and

and a relevant brain disorder, stroke. Here, they identify technical

sensitive recovery in the chronic stage of SCI.10 Such combined tar-

challenges that accompany cell transplantation, such as cell dose,

geting of neurogenesis and regeneration may be similarly applied to

timing, and delivery. In particular, they outline important preclinical

TBI, since the pathology of TBI manifests with impaired stem cell

investigations that are warranted to translate induced pluripotent

potencies, as recognized in the cell therapy campaign noted in the

stem cells for clinical applications in TBI and stroke.

other papers described here.5-7

Next, our laboratory further elucidates the potential benefits,

The articles in this special issue probe the pathology of CNS

as well as caveats associated with cell therapy for TBI.6 This review

trauma, including TBI and SIC, and begin to understand potential

paper tackles neuroinflammation as a major cell death mechanism

therapeutic modalities. Along this line, the proposed cell therapy5-7

that closely approximates the secondary cell death in TBI. We also

and drug and immunization treatments8-10 offer new directions in

recognize that because neuroinflammation ensues immediately after

the management of TBI. These promising therapies warrant serious

TBI onset but also persists over time, it presents a large therapeutic

consideration as we translate them into clinical applications.

window for cell therapy intervention. We provide encouraging laboratory studies detailing the success of cell transplantation in mitigat-
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ing the inflammation-plagued secondary cell death of TBI.
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Recognizing that cell therapy may not be a magic bullet, Willing
and co-workers7 offer a combination therapy. Here, they show the
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potential of combining cell therapy with drugs that target signaling
pathways of the neuro-immune-inflammatory axis. The concept posits that since singular targeting of a cell death pathway mostly fails,
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pass multiple targeting of cell death pathways. The paper by Dore
and teammates demonstrate the potential of engaging the lipid me-
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